Motivated by patients.

Built by us.

Twenty years ago, seven people founded a company with a simple mission: to create innovative drugs that make a meaningful difference in patients' lives. On January 5, 1998, this anti-infective drug development and metabolic engineering company was incorporated as Microbia, Inc. By the company's 10th anniversary, Microbia had ceased working on anti-infective programs and changed its name to Ironwood Pharmaceuticals, Inc. The decision to discontinue its anti-infective programs was made in order to prioritize the most promising programs, including a medicine that Ironwood discovered in its own labs, shepherded through clinical development, and brought to market so it could impact the lives of millions of patients - an achievement only a few companies in this industry have done before.

Ironwood has continued to grow, change, and thrive, with three commercial medicines, a pipeline of early- to late-stage candidates, and a committed and talented team who continue to shape and build the company.

In 2018, we are celebrating the 20th anniversary of Ironwood, the vital role played by each of our team members in its ongoing evolution, and the forward momentum that we believe will create a bright future for decades to come. The spirit at Ironwood is electric. We are motivated to make a difference for patients and build something of value.

And we're just getting started.

View Ironwood Timeline

Our Stories

: Giving (and Getting) Back: A Story of Basketball and Drug Development

Life at Ironwood

Giving (and Getting) Back: Basketball and Drug Development

Participating in the annual Bio-Ball to support Special Olympics Massachusetts has quickly become a favorite Ironwoodian pastime. But it’s about more than just having fun playing basketball for a great cause; our spirit of camaraderie on the court is reflected in our everyday interactions, and we value the journey as much as the goal itself.

Read More

: Four Thank You Notes on the Occasion of Ironwood′s 20th Anniversary

Lessons in Entrepreneurship

Four Thank You Notes

Milestones can be a cause for celebration and often provide an important opportunity for reflection. On the occasion of our 20th anniversary, Ironwood co-founder Brian Cali shares four thank you notes addressed to some of the many people who have made getting to this milestone possible.

Read More

: What Drives Innovation at Ironwood

Life at Ironwood

What Drives Innovation at Ironwood

At Ironwood, innovation is a way of life. We aren't afraid to ask big questions, follow a contrarian hypothesis, and take bold chances. We let the science lead us to research new therapeutic areas or classes of medicine. And innovation certainly isn't the sole province of R&D; everyone across the company pushes the boundaries of convention and strives for excellence.

Read More

: How Ironwood Makes Long-Term Success an Everyday Habit

20 Years Young & Growing

How Ironwood Makes Long-Term Success an Everyday Habit

For our 20th anniversary, we're more focused on the next 20 years - and beyond. Ironwood's team make the company's long-term success an everyday habit through an ownership mindset, boundless collaboration and a shared goal.

Read More

: A Visual History of Ironwood:<br/> 20 Years in 20 Photos

Life at Ironwood

A Visual History of Ironwood:
20 Years in 20 Photos

They say a picture is worth a thousand words. As we look back on the past 20 years, these images of both major milestones and small moments capture where we've been, who we are, and where we're going.

Read More

1998

Ironwood incorporated as Microbia, Inc., an anti-infective drug development, and metabolic engineering company. Founded by Peter Hecht, Brian Cali, Todd Milne, Eric Summers, Gerry Fink, Joe Cook, and Gina Miller, based on research and ideas generated at MIT's Whitehead Institute, Carberry's Bakery, and Peter's backyard.

Microbia opens first office in Cambridge with nine Ph.D. scientists, one small lab, one office, one conference room, and one computer.

First venture financing: We were fortunate to attract a syndicate of like-minded investors focused on long-term value, including venture firms Polaris, Venrock, and Aberdare, as well as a number of angel investors.

1999

Moved from our first real space on Memorial Drive to One Kendall Square and topped off a day of moving and cleaning with our first Halloween party — now a favorite annual tradition.

2000

Microbia core values unveiled — the foundation for Ironwood's present core values, depicted here.

2001

Hired 50th employee, our first medicinal chemist.

First Pizza Day, a tradition still greeted enthusiastically each month.

2003

First company wide contest held to name conference rooms after great drugs as part of our Great Drug Making initiative.

Established Great Drug Making Seminars, a series of lectures through which Ironwoodians seek to learn from the experiences of the drug developers who came before us.

The first-in-class GC-C agonist that would one day come to be known as LINZESS® (linaclotide) was selected for clinical development.

2004

Shed the last of our original anti-infective programs, a difficult decision but one based on our commitment to data-driven decision making and prioritization of the most promising programs.

Submitted investigational new drug application to the FDA to begin human clinical trials with linaclotide.

2007

Linaclotide Phase II data presented at Digestive Disease Week.

Entered into collaboration with Forest Laboratories, Inc. (which is now part of Allergan plc) to develop and commercialize linaclotide in North America.

2008

Microbia changed name to Ironwood Pharmaceuticals, Inc.

Moved headquarters to 301 Binney Street in Cambridge.

2009

Entered into a license agreement with Almirall S.A. for the development and commercialization of linaclotide in Europe. In 2015, Allergan subsequently acquired these rights from Almirall.

Hired our first commercial team member — one step closer to bringing medicines to patients.

Positive top-line data reported for two Phase III trials of linaclotide.

Entered into license agreement with Astellas Pharma, Inc. to develop and commercialize linaclotide in Japan.

2010

Ironwood initial public offering (IPO) on NASDAQ. Established our owner-related business principles to formalize our perspective on how we interact with investors.

2011

Linaclotide New Drug Application (NDA) submitted to FDA.

2012

Please see Important Risk Information below.

LINZESS® (linaclotide) approved by FDA.

Hired approximately 160 Clinical Sales Specialists, continuing our transition to a commercial biotech.

Entered into a collaboration agreement with AstraZeneca AB to co-develop and co-commercialize linaclotide in China, Hong Kong and Macau.

CONSTELLA® (linaclotide) approved in Europe.

LINZESS® launched and made available to patients in the United States.

2013

Gathered for our first Goalsapalooza, a now-annual tradition of celebrating progress toward corporate goals and our mission of empowering our team to deliver medicines to patients and value to shareholders.

Hosted our first Investor Day in New York City to showcase our progress developing innovative medicines for patients and building on our success with linaclotide to establish Ironwood as a leading therapeutics company.

2014

More than 1 million total prescriptions written for LINZESS®, according to Quintiles IMS.

2015

Top-line data reported from the Phase I study of IW-1973, our lead investigational soluble guanylate cyclase (sGC) stimulator.

2016

Entered into a license agreement with AstraZeneca plc for the exclusive U.S. rights to all products containing lesinurad, establishing a new franchise for Ironwood.

Please see Important Risk Information below.

ZURAMPIC® (lesinurad) launched in the U.S.

Ironwood, Allergan, and the American College of Gastroenterology (ACG) launched Picture My IBS, an art competition aimed at helping IBS patients share their journey with the disease through art, with a goal of improving communication between patients and their doctors and, ultimately, patient care.

Celebrated the holiday season with a new take on our annual holiday party centered on giving back. Our collective effort supported thousands suffering from hunger and provided holiday cheer to local families in need.

LINZESS® approved in Japan.

Top-line Phase IIb data reported for linaclotide delayed release (DR).

2017

Another dose of LINZESS® — 72mcg — approved in the U.S.

Expanded license agreement with Allergan (formerly Almirall) to partner on the potential development, manufacture and commercialization of linaclotide worldwide in all countries not previously covered by the agreement (other than China, Hong Kong, Macau, Japan and North America).

In partnership with patient advocacy group CreakyJoints, we conducted a survey of 1,000 gout patients and 500 caregivers and released compelling findings about misperceptions of the condition and its impact on daily life.

Positive top-line data reported from a Phase IIb trial of our product candidate being evaluated for persistent gastroesophageal reflux disease (GERD) — a condition affecting an estimated 10 million Americans.

DUZALLO® (lesinurad and allopurinol) approved by the FDA.

Please see Important Risk Information below.

In honor of the 5-year approval-versary of LINZESS®, a LINZESS® conference room was christened as part of our Great Drug Making program. The newly transformed room was unveiled at a ribbon cutting event.

Ironwood ranked sixth overall on Selling Power Magazine’s 2017 Best Companies to Sell For list.

DUZALLO® launched in the U.S.

Announced continued expansion of our sGC pipeline with mid-stage clinical trials evaluating our sGC stimulators in diabetic nephropathy, heart failure with preserved ejection fraction (HFpEF), achalasia, and sickle cell disease.

2018

Ironwood celebrates 20th anniversary!

Next page

LINZESS (linaclotide) capsules
72 mcg | 145 mcg | 290 mcg

What is LINZESS?

LINZESS® (linaclotide) is a prescription medication used in adults to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). "Idiopathic" means the cause of the constipation is unknown. It is not known if LINZESS is safe and effective in children less than 18 years of age.

IMPORTANT RISK INFORMATION

  • Do not give LINZESS to children who are less than 6 years of age. It may harm them. LINZESS can cause severe diarrhea and your child could get severe dehydration (loss of a large amount of body water and salt).
  • You should not give LINZESS to children 6 years to less than 18 years of age. It may harm them.
  • Do not take LINZESS if a doctor has told you that you have a bowel blockage (intestinal obstruction).

Before you take LINZESS, tell your doctor about your medical conditions, including if you are:

  • Pregnant or plan to become pregnant. It is not known if LINZESS will harm your unborn baby.
  • Breastfeeding or plan to breastfeed. It is not known if LINZESS passes into your breast milk.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Side Effects

LINZESS can cause serious side effects, including diarrhea, the most common side effect, which can sometimes be severe. Diarrhea often begins within the first 2 weeks of LINZESS treatment. Stop taking LINZESS and call your doctor right away if you get severe diarrhea during treatment with LINZESS.

Other common side effects of LINZESS include gas, stomach-area (abdominal) pain, swelling, or a feeling of fullness or pressure in your abdomen (distension). Call your doctor or go to the nearest hospital emergency room right away if you develop unusual or severe stomach-area (abdominal) pain, especially if you also have bright red, bloody stools or black stools that look like tar.

These are not all the possible side effects of LINZESS. For more information, ask your doctor or pharmacist.

Please see Medication Guide and full Prescribing Information.

DUZALLO® (lesinurad and allopurinol) tablets
200 mg / 300 mg
Important Safety Information

DUZALLO can cause serious side effects

Kidney problems: Some people taking DUZALLO may have kidney problems such as a sudden decrease in kidney function (acute kidney failure). Your healthcare provider may do blood tests to check your kidneys while you are taking DUZALLO.

Serious skin rash and serious allergic reactions: Severe and potentially life-threatening allergic reactions and skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis and exfoliative dermatitis have been reported in some people taking allopurinol, one of the components of DUZALLO. Stop taking DUZALLO and get emergency medical help if you have any of the following symptoms:

  • skin rash; blistering of the skin, mouth, nose, and genitals
  • painful red or purple skin that looks burned and peels off
  • joint pain; swollen glands
  • red, painful, watery eyes; persistent itching; hives
  • fever

Liver Problems: Liver problems can happen in people who take DUZALLO. Call your healthcare provider if you have any of the following symptoms: loss of appetite, weight loss, feeling very tired, nausea or vomiting, yellowing of your skin or the white part of your eyes, itching, dark or brown (tea-colored) urine, or pain on the upper right side of your stomach.

Heart Problems: People who take DUZALLO can have serious heart problems including heart attack and stroke. It is not known that DUZALLO causes these problems.

Blood Problems: DUZALLO can affect your bone marrow and cause low red blood cells, white blood cells and platelets. If your blood cell counts become very low, you can get infections or have bleeding problems. Taking DUZALLO with certain other medicines can increase your chance of having blood problems.

Drowsiness: DUZALLO can cause you to be drowsy. Do not drive, operate heavy machinery, or do other dangerous activities until you know how DUZALLO affects you.

The most common side effects of DUZALLO include headache, flu, higher levels of blood creatinine (a measure of kidney function), heartburn (acid reflux), skin rash, nausea, and diarrhea. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of DUZALLO. For more information, ask your healthcare provider or pharmacist.

What is DUZALLO?

DUZALLO is a prescription medicine that contains 2 medicines, a URAT1 inhibitor called lesinurad and a xanthine oxidase inhibitor called allopurinol. DUZALLO is used to lower uric acid levels in the blood in people with gout, when allopurinol alone has not worked well enough.

Please see Medication Guide and full Prescribing Information, including Boxed Warning.

ZURAMPIC® (lesinurad) tablets
200 mg
Important Risk Information
  • Some patients taking ZURAMPIC may have kidney problems such as a sudden decrease in kidney function (acute kidney failure). This is more common when ZURAMPIC is taken without a xanthine oxidase inhibitor such as allopurinol or Uloric
  • ZURAMPIC should always be taken with a xanthine oxidase inhibitor

Do not take ZURAMPIC if you have severe kidney problems, have received a kidney transplant or are on dialysis, have a fast breakdown of cancer cells that can lead to high uric acid (tumor lysis syndrome), or have a rare inherited condition that causes too much uric acid in the blood (Lesch-Nyhan syndrome).

Before taking ZURAMPIC, tell your doctor about all of your medical conditions, including if you:
  • Are pregnant or plan to become pregnant
  • Are breastfeeding or plan to breastfeed

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ZURAMPIC may affect the way other medicines work, and other medicines may affect how ZURAMPIC works.

ZURAMPIC may cause serious side effects including heart problems. People who take ZURAMPIC can have serious heart problems, including heart attack and stroke. It is not known that ZURAMPIC causes these problems.

The most common side effects of ZURAMPIC are headache, flu, higher levels of blood creatinine (a measure of kidney function), and heartburn.

Tell your doctor if you have any side effects that bother you or that do not go away. These are not all of the possible side effects of ZURAMPIC.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For more information, ask your doctor or pharmacist.

ZURAMPIC is a prescription medicine used together with a xanthine oxidase inhibitor such as allopurinol or Uloric in adults with gout who still have a high uric acid level.

Please see Medication Guide and full Prescribing Information, including Boxed Warning.